ABSTRACT. The gut is supplied with its own nervous system, referred to as the enteric nervous system (ENS). It regulates the various functions of a digestive system such as motility, secretion and digestion and has close interactions with the enteric immune system. The aim of this study was to investigate the alterations of the ENS in dexamethasone-treated rats using two general neuroendocrine markers: protein gene product 9.5 (PGP 9.5) and synaptophysin (SY). As concluded from the changes in a pattern of immunoexpression of the markers applied, some remodeling of the ENS occured. Further investigations are needed to elucidate in more details its nature and importance with respect to gastrointestinal complications seen in diabetes.
INTRODUCTION
The neuroendocrine system of the gut is its regulatory system consisting of enteroendocrine cells scattered among the epithelial cells and the neurons and nerve fascicles of the enteric nervous system (ENS), forming a neural network embedded in the wall of the gastrointestinal tract (GIT). The functional classes of enteric neurons are sensory neurons involved in monitoring of the conditions in the gut, interneurons, which integrate this information and motor neurons, either stimulatory or inhibitory, that control motility, secretion and digestion in the gut. In addition, the ENS contains glial cells as well as interstitial cells of Cajal (COSTA et al., 2000; NEZAMI and SRINIVASAN, 2010) . The most of the enteric nerve cells are arranged into two mutually interconnected nerve plexuses: myenteric (Auerbach's) and submucosal (Meissner's).
The myenteric plexus is located between the two muscle layers of muscularis externa and is involved in the regulation of relaxation and contraction of the intestinal wall (FURNESS and COSTA, 1987) . Its ganglia and interconnecting nerve fibers form a polygonal network (SMITH, 1970) . The nerve fibers are divided into primary, secondary and tertiary, where first two are interganglionic, and the latter are ramified into the adjacent muscle layers. In both muscle layers, an aganglionated plexus exists in a form of a dense network of fine nerve fibers oriented parallel to the course of the corresponding smooth muscle cells (WEDEL et al., 1999).
The ganglia of the submucosal plexus are composed of a densely packed neuron bodies, that are surrounded by glial cells and terminal bundles made up of nerve fibers (GULBRANSEN, 2014) . The neurons of the submucosal plexus innervate glandular epithelium, muscularis mucosae, intestinal endocrine cells and submucosal blood vessels and are involved in the regulation of mucosal blood flow and epithelial cells function, as well as in the detection of nutrients in the enteric lumen (SANOOP et al., 2012; NEUNLIST and SCHEMANN, 2014) .
The ENS acts independently of the central nervous system (CNS) (GOYAL and HIRANO, 1996) and can be considered as the third component of the autonomic nervous system. It acts through local reflexes (FURNESS et al., 1995) and interactions with the autonomous system (FURNESS et al., 2014) and endocrine cells of the tract itself (SCHUTTE et al., 1997; FURNESS, 2016) . In addition to the mentioned functions, the ENS is also involved in the regulation of immune and inflammatory processes in the gut (COOKE, 1994) .
The enteric neurons perform their activities through more than 25 neurotransmitters (in most neurons several of them being colocalized), such as acetylcholine, serotonin, gastrin, VIP, NO, NPY, galanin, ATP, GABA etc. (GERSHON et al., 1994; MCCONALAGUE and FURNESS, 1994; SONG et al., 1997) .
Diabetes mellitus is a disease that causes damage in almost all of the organic systems of animals and humans, leading to numerous and serious health complications. Bearing in mind the role of the ENS in the control of the GIT function, it can be assumed that gastrointestinal symptoms common in patients with diabetes mellitus, such as nausea, For that reason, the aim of this study was to investigate an alteration in the intensity of the gut wall innervation by ENS in dexamethasone-treated rats, as an experimental model of a prediabetic stage/diabetes mellitus type 2 (MULDER, 1997). The innervation of the gut wall was assessed on the basis of the immunoexpression of the protein gene product 9.5 (PGP 9.5) and synaptophysin (SY) as general markers of neurons and neuroendocrine cells (THOMPSON et al., 1983; CALAKOS and SCHELLER, 1994) .
MATERIALS AND METHODS

Animals and tissue preparation
Twenty male Wistar rats (obtained from the vivarium of the Vinča Institute of Nuclear Sciences, Belgrade, Republic of Serbia) aged 30 days were kept in standardized laboratory conditions (a 12/12 h light/dark cycle at 22°C), in metabolic cages. A standard laboratory rat chow diet and tap water were available ad libitum. The animals were randomly allocated into the control (C, 10 rats) and dexamethasone-treated (D, 10 rats) groups. The animals of the group D were injected with dexamethasone dissolved in the saline (2 mg kg -1 , i.p. during 12 days) while the rats of the group C received the saline only. After the experimental period, the animals were fasted overnight and sacrificed in a light ether anesthesia. This protocol was approved by the Serbian Animal Use Committee. The experiment was performed according to the rules of animal care proposed by the Serbian Laboratory Animal Science Association.
Preparation of histological sections for immunohistochemistry
The tissue specimens (different parts of the gut -jejunum, ileum, caecum and colon) from all the animals were fixed in Bouin's fluid, embedded in paraffin and cut into 5 µm thick sections. The immunohistochemical examination of the ENS was performed using two markers -PGP 9.5 and SY. The immunohistochemistry was carried out by the streptavidinbiotin immunoperoxidase technique (LSAB+/HRP kit, Dako, Carpinteria, CA) using the antisera against SY (diluted 1:50, overnight incubation at 4°C; Dako, Carpinteria, CA, Code No. A0010) and PGP 9.5 (diluted 1:25, overnight incubation at 4°C; Dako, Carpinteria, CA, Code No. Z5116), following the manufacturer's recommendations. Visualisation of reaction sites was done by AEC Substrate Chromogen. The sections were then counterstained with hematoxylin. The analysis was performed on the Olympus light microscope at an objective magnification of x 20. The intensity of immunoexpression was semiquantified independently by three observers and presented as strong (+++), moderate (++), weak (+) or no reaction (-).
RESULTS
The results obtained for the immunoexpression of PGP 9.5 and SY are shown in Table 1 . The immunoreactivity to PGP 9.5
In both jejunal plexuses (submucosal and myenteric) of animals from the D group, the PGP 9.5 immunoexpression was stronger than in the C group (Fig. 1a, b) , being particularly prominent in the myenteric plexus. In the ileum, the pattern of immunoexpression was generally similar (Fig. 1c, d ). In the myenteric plexus of the caecum, reaction was stronger after treatment with dexamethasone (Fig. 1e, f) . In the colon, there was no difference in the intensity of reaction between the groups (Fig. 1g, h ). Overall, a stronger PGP 9.5-immunoreactivity was recorded in the examined regions of the gut of dexamethasone-treated animals, as compared to the control. In both groups, the part of the gut that showed the most prominent reaction was the ileum. In all animals studied, the strongest reaction was at the level of the myenteric plexus.
The immunoreactivity to SY
In the myenteric plexus of the jejunum of the dexamethasone-treated rats, SY immunoreaction was stronger than in the control group, but it was absent in submucosal plexus, as opposed to controls with a weak reaction (Fig. 2a, b) . In the ileum, the pattern of SY immunoexpression was generally similar in both groups of animals, with the stronger reaction in the myenteric plexus (Fig. 2c, d ). In the caecum, a relatively low level of reaction was observed in both groups of rats, with complete absence of immunostaining in the submucosal plexus of the control (Fig. 2e, f) . On the contrary, the SY immunoexpression in the colon of both control and dexamethasone-treated animals was generally at the high level (Fig. 2g, h) . Overall, the immunoreactivity to SY was most prominent in the myenteric plexus, in both groups of animals. 
DISCUSSION
The dexamethasone is a synthetic glucocorticoid frequently used in the therapy of different diseases and conditions including inflammation, bacterial infections, autoimmune diseases, graft versus host disease and even in some forms of cancer (COOK et al., 2016) . Unfortunately, the dexamethasone treatment is usually associated with undesirable sideeffects, some of which might be serious as the primary disease itself. Previous studies, evaluating effects of the dexamethasone in humans and animals, reported a strong relationship between its use and impaired glucose homeostasis (PAQUOT et al., 1995; KWON and HERMAYER, 2013) , which after a prolonged treatment can lead to the development of diabetes mellitus type 2 (OGAWA et al., 1992) . Thus, this side-effect makes dexamethasone suitable for use as a diabetogenic agent in different animal models of diabetes (MULDER, 1997; KING, 2012) .
Given that gastrointestinal disorders involving motility impairment are relatively common in diabetic patients, this study (as a part of the wider research) was designed to investigate the alterations in the intensity of the ENS innervation of defined regions of small and large intestine, using animal model of dexamethasone-induced prediabetes/diabetes type 2 (MULDER, 1997). Based on the previously reported results (KOKO et al., 2001; GLIŠIĆ et al., 2006) , which emerged from the above-mentioned comprehensive research, we already showed that same treatment caused hypoglycemia, glycosuria, increase in plasma and pancreatic insulin levels, as well as the strong hypertrophy and hyperplasia of the pancreatic B cells, together indicating the impaired glucose tolerance and diabetic state.
In order to visualize the ENS elements, we used the immunohistochemical expression of PGP 9.5 and SY as markers (LUNDBERG et al., 1988; CALAKOS and SCHELLER, 1994) . Otherwise, the topography and structure of the ENS were investigated in the past mainly using a silver impregnation (KUMAR and PHILLIPS, 1989) and whole mount immunohistochemistry with antibodies against the PGP 9. The results of this study showed a rather uniform expression of the PGP 9.5 along the investigated gut regions of untreated rats, with only slightly stronger reaction in the myenteric plexus of the ileum and colon. The dexamethasone treatment induced the increase of PGP 9.5-immunoreaction in submucosal plexus of jejunum and ileum, and in myenteric plexus of jejunum and cecum. Thus, after the dexamethasone treatment, the total PGP 9.5-immunoreactivity was stronger than in the control rats. Also, the immunoreactivity was stronger in the segments of the small intestine than in those of the large intestine. In respect to the SY-immunoreactivity in the control animals, it varied along the intestinal segments, being mainly stronger in the myenteric plexus of all segments. The treatment with dexamethasone mainly caused the increase of immunoreactivity, except in the submucosal plexus of the jejunum.
In general, the dexamethasone treatment induced increase in the PGP 9.5-and SYimmunoreactivity in nerve plexuses of intestine regions studied. The increase in the PGP 9.5-immunoreactivity in some parts of the intestine wall could indicate proliferation of neural elements (Lundberg et al., 1988) . Similarly, SY expression as a marker for synaptic density (MASLIAH et al., 1990) , an increase in the SY-immunoreactivity may suggest a regeneration of neurons and consequently more intensive synaptic transmission (DZIENIS- KORONKIEWICZ et al., 2005) .
The more intensive innervation of the intestine wall by the ENS, observed in the animal model of prediabetes/diabetes type 2 used in the present study, may cause more or less inappropriate activity of the intestine in food processing, such as accentuated secretion, absorption and motility (peristaltic wave). We believe that such changes might lead to digestive disturbances expected to be the most pronounced at the jejunal level, where the most of the food absorption takes place.
In relation to the ENS in diabetes, it is known that changes exist in the enteric neuronal size, number (ZANONI at al., 1997; FURLAN et al., 2002) and morphology (axonal swelling) as well as in the neurotransmitter expression (SPÅNGÉUS et al., 2000; CHANDRASEKHARAN and SRINIVASAN, 2007) . It seems that in the initial phase of diabetes there is a loss of neurons, after which the regenerative phase follows (ADEGHATE et al., 2003) . Generally, diabetes is associated with the loss of inhibitory neurons and the increase in excitatory neurons (HE et al., 2001; IWASAKI et al., 2006) .
The dexamethasone-treated animals in the present study, developed diabetes similar to human diabetes mellitus type 2 (GLIŠIĆ et al., 2006) and changes in the enteric innervation occurred, likely in the direction to neuronal regeneration. This is consistent with the literature data (ADEGHATE et al., 2003; CHANDRASEKHARAN and SRINIVASAN, 2007) . It could be a compensatory response to a loss of some type of enteric neurons after the applied treatment.
Generally, the observed changes in the number, density and ultrastructure of the gut endocrine cells in our previous reports (KOKO et al., 2001; GLIŠIĆ et al., 2006; KOKO et al., 2008; GLIŠIĆ et al., 2011) as well as the changes in the ENS in the dexamethasone-treated rats, presented in this study, indicate a likely disturbed bowel motility and secretion. The disturbance of the gut motility and secretion interfere with normal metabolic processes of food digestion, which may lead to impaired glucose homeostasis and the development of other symptoms and complications of diabetes mellitus type 2.
CONCLUSIONS
The evidences obtained from this study showed that the dexamethasone treatment induced changes in the intensity of the ENS innervation of the gut wall, which may be related to digestive dysfunctions commonly seen in diabetes. However, further investigations are needed to elucidate in more details the nature of observed alterations of ENS.
